Deriving clinically meaningful cut-scores for fatigue in a cohort of breast cancer survivors: a Health, Eating, Activity, and Lifestyle (HEAL) Study by Stover, Angela M. et al.
Deriving Clinically Meaningful Cut-scores for Fatigue in a Cohort
of Breast Cancer Survivors: a Health, Eating, Activity, and
Lifestyle (HEAL) Study
Angela M. Stover1, Bryce B. Reeve1,*, Barbara F. Piper2, Catherine M. Alfano3, Ashley
Wilder Smith3, Sandra A. Mitchell3, Leslie Bernstein4, Kathy B. Baumgartner5, Anne
McTiernan6, and Rachel Ballard-Barbash3
1University of North Carolina-Chapel Hill
2National University
3National Cancer Institute
4City of Hope National Medical Center
5University of Louisville
6Fred Hutchinson Cancer Research Center
Keywords
cancer-related fatigue; breast cancer survivors; measurement; Piper Fatigue Scale; health-related
quality of life
Introduction
Cancer-related fatigue (CRF) is increasingly recognized by clinicians, researchers, and
survivors as a debilitating symptom requiring clinical attention that may negatively impact
quality of life [1–4]. At the same time, there is evidence that CRF continues to be under-
evaluated and under-treated [5–8]. Guidelines for the clinical management of CRF have
been developed by the National Cancer Institute (NCI), National Comprehensive Cancer
Network (NCCN), the Fatigue Coalition, and other task force organizations [9–15]. The
NCCN guidelines recommend utilizing a single item with a 0–10 severity metric to screen
for CRF but consensus for determining clinically meaningful thresholds for categorizing
cancer patients as experiencing mild, moderate, or severe fatigue is in its infancy [10–11].
More than twenty patient-reported measures of fatigue are in use in oncology research and
practice to assess both the fatigue experience and impact of fatigue on health-related quality
of life (HRQOL) [16–22]. To enhance consistency and precision in population-based and
clinical research, fatigue scores need to be interpreted using clinically meaningful threshold
descriptions that accurately characterize the level of CRF and its impact on HRQOL.
Several studies have demonstrated that baseline fatigue severity scores can predict fatigue
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severity levels over time in patients on active treatment [4, 23–24]. Thus, classifying
patients into severity thresholds at baseline and following these levels over time is becoming
increasingly important in practice and research.
Conventionally in practice, a fatigue severity cut-score of ≥ 4 on a 0–10 scale has been used
as a cut-off score to make treatment decisions [e.g., 18]. However, empirical derivations of
clinically meaningful cut-points of mild, moderate, and severe fatigue are limited. Each
threshold level may have implications for risk-stratification into levels of clinical care such
as when intervention with medication to reduce fatigue is warranted. For instance,
Bupropion sustained-release and Modafinil are observed to reduce severe and impairing
fatigue in cancer patients but their effects on mild or moderate CRF is less certain [25–28].
Further, classifying patients into fatigue levels can be used to better interpret response to
treatments and optimize research designs through participant selection criteria. For example,
the magnitude of change that can be demonstrated in response to an intervention is
optimized by designs that select study participants across the continuum of fatigue [29].
Sexual functioning is also an important dimension of HRQOL that has been shown to be
positively correlated with fatigue but the relationship is largely unexplored [30–31]. Similar
to fatigue, sexual dysfunction is common yet under-recognized and under-treated [32–34].
Sexual dysfunction can also persist during survivorship despite recovery in other domains
such as physical functioning [1, 32–34]. The normal process of aging and loss of estrogen
over time for postmenopausal women are known to impact sexual function with
approximately 35% of older U.S. women reporting difficulty with orgasm and 44%
reporting lack of sexual interest [35]. Beyond aging processes, breast cancer survivors have
unique considerations such as chemotherapy-induced ovarian failure [30, 34, 36]. Women
with hormone-receptor positive tumors may be advised to avoid postmenopausal estrogen
therapy and may be prescribed tamoxifen to prevent estrogen from binding to breast cancer
cells, which also may impact sexual function and fatigue [34].
With these considerations in mind, the aim of our study was to empirically determine
clinically meaningful fatigue severity thresholds (cut-scores within a 0–10 scale metric) for
the 22-item Piper Fatigue Scale-revised (PFS-R) [37] and its shortened 12-item version
(PFS-12) [38] in a cohort of breast cancer survivors. The PFS-R and PFS-12 are
multidimensional and include key dimensions of the fatigue experience including cognition,
behaviors, affect, and sensory symptoms [37–38]. We examined five candidate models of
fatigue severity thresholds where breast cancer survivors could be classified on the PFS-R or
PFS-12 as none, mildly, moderately, or severely fatigued on a 0–10 metric. We then
examined the association of these ordered fatigue classifications with changes in HRQOL
(physical, mental, and sexual health).
Methods
Participants
The Health, Eating, Activity, and Lifestyle (HEAL) Study is prospectively following a
multi-site cohort of women newly diagnosed with stages 0-IIIa breast cancer [1, 39]. The
HEAL study was designed to examine the influence of body mass, health behaviors, sex
hormones, and genetic factors on long-term breast cancer outcomes. The HEAL Study
enrolled 1,183 women from SEER (Surveillance, Epidemiology, and End Results) cancer
registries in the United States who were diagnosed between 1995–1999. Comparisons
between women enrolled in HEAL and women eligible in SEER have been published
previously [39]. Of the 1,183 enrolled, 858 (73%) completed a HRQOL battery
approximately 3 years after diagnosis. Reasons for non-participation in the HRQOL
assessment included death (n=75), refusal to participate (n=140), inability to contact (n=99),
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and too ill to complete questionnaire (n=11) [1]. In the current study, one woman with
incomplete data was excluded resulting in a final sample size of 857 women.
Women were recruited from three SEER registries: New Mexico: 457 (53%); Western
Washington: 177 (21%); and Los Angeles County: 223 (26%). By design, the majority of
African American survivors were enrolled at the Los Angeles County site and the majority
of Hispanic survivors were enrolled at the New Mexico site [1, 39]. In addition, each site
had different age restrictions due to ongoing clinical trials (Los Angeles County: ages 35–
64; Western Washington: 40–64; and New Mexico: ≥18). In analyses, we controlled for both
age and race/ethnicity to minimize potential differences across groups. Women who
experienced a recurrence or new primary breast cancer were included in analyses (n=57 or
7%) as research suggests that these women may be at risk for experiencing higher levels of
fatigue [40]. In terms of measurement, having breast cancer survivors across the continuum
of fatigue is desirable [29].
This study was approved by the Institutional Review Board at each site. Each woman
provided informed consent to participate prior to enrollment.
Data Collection
The baseline assessment was completed as an in-person interview within one year of
diagnosis with breast cancer. Women reported their age at diagnosis, level of education,
racial and ethnic background, and height [1]. The follow-up HRQOL assessment occurred
approximately 3 years after diagnosis (i.e., 2 years after baseline). At follow-up, survivors
reported demographics, comorbid conditions, and medication use (including tamoxifen and
antidepressants) and were weighed by staff [1, 39]. HRQOL data included the 22-item PFS-
R [37], the Medical Outcome Study short form-36 questionnaire (SF-36) [41], and the
Sexual Functioning subscale of the Cancer Inventory for Problem Situations (CIPS) [42].
Clinical data such as stage and treatment type were collected from SEER medical record
abstraction [1, 39].
The 22-item PFS-R, and its shorter version, the 12-item PFS-12, have 4 subscales:
Behavioral, Affective, Sensory, and Cognitive [37–38]. Subscale scores are added together
and divided by 4 to obtain a total fatigue score bound between 0 and 10 where higher scores
reflect more fatigue [37–38]. The HEAL Study employed an adapted recall period for the
PFS-R, asking survivors to rate their fatigue over the past month rather than the past week
[1]. This extended recall period was intended to capture a general state of fatigue rather than
acute episodes that may not be representative of survivors’ overall fatigue experiences. The
shorter PFS-12 was developed in a separate study using data from the same HEAL cohort by
retaining items with the best psychometric properties including content validity [38].
Support was demonstrated for both an overall fatigue factor in the PFS-R and PFS-12 [38].
In the current study, Cronbach’s alpha reliability for the PFS-R scale was .96 and .92 for the
PFS-12.
The SF-36 has eight subscales (physical functioning, general health, role physical, bodily
pain, mental health, role emotional, social functioning, and vitality) that range from 0–100
where higher scores indicate better HRQOL [41]. Two component scores are calculated
based on weights applied to the subscales: a Physical Component Summary (PCS) score and
a Mental Component Summary (MCS) score [41, 43]. Scores are normalized to the general
U.S. population on a T-score metric (mean of 50 and SD of 10) and a score change of a half
standard deviation (5 points) has been demonstrated to be clinically meaningful [41, 43].
Population norms are provided for gender and age range categories [41, 43]. Cronbach’s
coefficient alpha reliability for the SF-36 subscales ranged from .78–.87.
Stover et al. Page 3













The Sexual Functioning subscale of the Cancer Inventory of Problem Situations (CIPS) is
scored from 0 (not a problem) to 3 (serious problem) and higher scores indicate worse
sexual functioning [42]. The CIPS sexual functioning subscale assesses physical and
psycho-social aspects of sexual health including lack of sexual interest, difficulty in
becoming aroused, inability to relax and enjoy sex, and difficulty in having an orgasm [42].
Given that no publications are available that assess clinically meaningful differences in
CIPS scores, we used .3 to .5 of a standard deviation to define a minimally important
difference [44–47]. Cronbach’s coefficient alpha reliability for pre-diagnosis sexual
functioning was .87 and post-diagnosis was .92.
Comorbid conditions were assessed by asking each woman if a doctor or other health
professional had ever informed her that she had each of 18 health conditions such as
diabetes, cardiovascular disease, and arthritis [1]. Endorsement of a health condition was
followed with a question assessing whether the condition limited activities. A comorbid
health condition index was calculated by summing the number of health conditions that limit
activities. Body mass index (BMI) was calculated as kg/m2.
Clinical and treatment data were collected from the SEER cancer registries. The registries
abstract clinical data from pathology reports about tumor size and grade, lymph node status,
and hormone receptor status. HEAL provides a calculated variable for disease stage across
versions of the American Joint Committee on Cancer (AJCC) Cancer Staging Manual that
was applicable at the time of diagnosis [48].
Analyses
We examined five candidate models of fatigue severity thresholds (cut-scores within the 0–
10 scale metric) where breast cancer survivors could be classified on the PFS-R and PFS-12
as none, mildly, moderately, or severely fatigued (see Figure 1). Model A reflected cut-
scores based on clinical judgment and historical use with the PFS-R [1, 39]. Model A is also
consistent with thresholds identified on a similar fatigue measure, the Brief Fatigue
Inventory [22]. Models B-E were generated by expanding and contracting the threshold
categories based on clinical and measurement-related considerations.
To evaluate which of the five models yielded optimal cut-scores for fatigue severity on the
PFS-R and PFS-12, we used multivariate analysis of covariance (MANCOVA) [49].
MANCOVA controls for inflation of the type I error rate by conducting an overall test of
multiple dependent variables (with multiple covariates), and produces several F-values
including Wilk’s lambda, Pillai’s trace, and Hotelling’s trace [49]. Consistent with standard
MANCOVA methodology and prior work on other fatigue scales, the highest combination
of F-values was used to determine optimal threshold models that demonstrate the highest
discrimination among fatigue levels [22]. Each model’s fatigue severity cut-scores (i.e.,
Models A-E) were used as the between-subjects variable in the MANCOVA. Given that
there is neither a gold standard nor objective way to measure fatigue such as a biomarker,
the four SF-36 Vitality items were used as the dependent variables in the MANCOVA
model. The SF-36 Vitality items include “feeling full of life,” “worn out,” “tired,” and “have
a lot of energy” [41]. The Vitality subscale has been shown to be high performing in terms
of reliability, validity, and robust psychometric properties for use with breast cancer patients
and survivors [50–52]. In addition, SF-36 scores are normalized to the U.S. population [41].
A previous HEAL Study analysis found a 79% concordance rate for classifying breast
cancer survivors on fatigue using the SF-36 Vitality items and the PFS-R [1].
We then examined the association between identified cut-scores and decrements in HRQOL
(SF-36 subscales and summary scores, and CIPS sexual functioning scale). The SF-36
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Vitality subscale was not reported as a single subscale outcome given that these items were
used to determine cut-scores (but it is one component of the PCS and MCS calculations).
Multivariate regression was used to model the variation in HRQOL explained by fatigue,
adjusting for demographic characteristics (age, race, education), treatment-related variables
(stage, type of treatment, tamoxifen use), comorbid health conditions that limit activities,
and antidepressant use to minimize potential differences across groups. These variables were
chosen given their positive associations with fatigue in prior research and the HEAL
sampling design [1, 39, 53–56]. Models with sexual functioning as an outcome variable also
included baseline sexual functioning as a covariate. BMI was not significantly related to the
PFS-R or PFS-12 and thus, was not used as a covariate (correlation r = .04, p = .24 and r=.
05, p = .15; respectively).
Results
Sample Characteristics
The demographic and clinical characteristics for the 857 breast cancer survivors are
provided in Table 1. Age at diagnosis ranged from 29–86 years with a mean of 55
(SD=10.31). At baseline (within 1 year of diagnosis), 67% of women reported being non-
Hispanic Caucasian, 76% were post-menopausal, and 25% had completed high school or
less education. The majority of survivors had been diagnosed as in situ or Stage I (62%), had
undergone a partial mastectomy including breast-conserving surgery (64%), and had
completed adjuvant therapy (68%). Fifty-seven women (7%) experienced a recurrence (or
new primary breast cancer) between baseline and 3 years post-diagnosis. At the time of the
HRQOL assessment (approximately 3 years after diagnosis), 57% were working, over half
of the cohort had a BMI of 25 kg/m2 or more (56%), and 72% reported one or more
comorbid condition(s).
Model Results
The PFS-R and PFS-12 mean scores were 3.9 with a range from 0 – 9.92 (SD ~2.0). As
expected, the correlation between the PFS-R and the SF-36 Vitality subscale was high (r =
−0.73, p<.0001; correlation with PFS-12: r= −0.73, p<.0001). Table 2 includes adjusted
MANCOVA results for the five candidate fatigue cut-score models in descending order by
F-values. With the SF-36 Vitality items used as the dependent variables, Models A and D
showed the highest magnitude of F values over Models B, C, and E. Thus, we will present
results for only Models A and D for the PFS-R and PFS-12 in the rest of the paper.
Associations of PFS-R and PFS-12 Fatigue Cut-Scores with HRQOL Decrements
Mean scores for the SF-36 subscales ranged from 45.82 (SD=11.06, physical function) to
49.98 (SD=10.80, bodily pain). Correlations between the PFS-R and SF-36 subscales ranged
from −0.35 (PFS-R and Physical Function, p<0. 01) to −0.61 (PFS-R and MCS, p<0. 01).
Mean sexual functioning and the PFS-R were correlated at .27, p<.01. Correlations between
the PFS-12 and SF-36 Summary Scores ranged from −0.37 (PFS-12 and Physical Function,
p<0. 01) to −0.59 (PFS-12 and MCS, p<0. 01). Mean sexual functioning and the PFS-12
were correlated at .28, p<.01. All correlations were statistically significant at the .01 level
and the magnitudes suggest moderate to strong associations between fatigue and HRQOL
domains.
Figure 2 provides comparison graphics between Models A and D for the PFS-R and PFS-12
and incremental decrements in physical and mental functioning as fatigue thresholds
increase. For both Models A and D, women classified as having no fatigue on the PFS-R
and PFS-12 had the highest scores in every SF-36 domain and women classified as severe
Stover et al. Page 5













fatigue had the lowest scores. For Model A on the PFS-R and PFS-12, 8 out of 9 HRQOL
domains demonstrated threshold values that were significantly different for breast cancer
survivors for each level of none, mild, moderate, and severe fatigue (PCS, MCS, general
health, bodily pain, role physical, mental health, social functioning, and role emotional).
The single case of confidence intervals overlapping occurred in the physical functioning
categories for none and mild fatigue (Model A PFS-R no fatigue 95% CI: 47.93 – 53.49,
mild fatigue 95% CI: 47.56 – 49.44). The 95% confidence intervals for the none and mild
fatigue categories for the PFS-12 were very close (Model A PFS-12 no fatigue 95% CI:
47.93 – 53.49, mild fatigue 95% CI: 47.56 – 49.44). Breast cancer survivors with none and
mild fatigue reported physical functioning scores similar to the mean U.S. population of
women aged 55–64.
Model D for the PFS-12 showed similar results to Model A with confidence intervals
overlapping for the categories of none and mild fatigue for physical functioning (Model D
PFS-12 no fatigue 95% CI: 49.49 – 53.67, mild fatigue 95% CI: 48.08 – 50.22). However,
Model D for the PFS-R was less able to discriminate between survivors categorized as none
and mild fatigue. The domains of PCS, physical functioning, role physical, and social
functioning had overlapping confidence intervals for the categories of none and mild fatigue
when assessed by the PFS-R and Model D.
The mean score for sexual functioning was 0.43 (SD=0.57) for pre-diagnosis and 0.88
(SD=0.80) for post-diagnosis. Figure 3 shows the incremental decrements in post-diagnosis
sexual functioning that occurred as fatigue cut-scores increased. Model A for the PFS-R had
overlapping confidence intervals for the categories of mild and moderate fatigue for lack of
sexual interest; and moderate and severe fatigue for difficulty with arousal, inability to relax
and enjoy sex, and difficulty with orgasm. Model A for the PFS-12 had overlapping
confidence intervals for 2 of 4 sexual functioning items: mild and moderate fatigue for
difficulty with arousal; and moderate and severe fatigue for difficulty with orgasm. Model D
assessed by the PFS-R and PFS-12 had overlapping confidence intervals for the categories
of mild and moderate for all 4 sexual functioning items: lack of sexual interest; difficulty
with arousal; inability to relax and enjoy sex; and difficulty with orgasm.
Table 3 shows that approximately 40% of the variance in the PCS was explained by Models
A and D for both the PFS-R and PFS-12. Approximately 30% of the variance in the MCS
and sexual health was explained by Models A and D for the PFS-R and PFS-12.
As a sensitivity analysis, the cut-point models and associations with HRQOL were re-run
excluding 57 women who experienced a cancer recurrence. Identical results were observed
(data not shown) with the exception of larger confidence intervals for the severe fatigue
category given fewer women in this category.
Discussion
We examined five models of fatigue severity cut-scores on the 22-item PFS-R and 12-item
PFS-12 [37, 38] with a population-based cohort of breast cancer survivors approximately
three years after diagnosis. Using the SF-36 Vitality subscale as a comparison measure for
fatigue, two cut-score models showed the best discrimination among fatigue categories: A
(0=no fatigue, 1–3=mild, 4–6=moderate, 7–10=severe fatigue) and D (0=no fatigue, 1–
2=mild, 3–5=moderate, 6–10=severe fatigue). Severity levels of fatigue determined by
Models A and D explained about 40% of the variance in the SF-36 PCS and about 30% in
the MCS and sexual functioning. Previous research has primarily described the relationship
between severity of fatigue and HRQOL in terms of correlational analyses [e.g., 52]. Our
analyses extend this research by examining decrements in the HRQOL facets of physical,
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mental, and sexual functioning within each threshold for none, mild, moderate, and severe
fatigue.
With only a few notable exceptions, we found that each threshold of worsening levels of
fatigue in Models A and D was associated with statistically and clinically meaningful
decrements in physical, mental, and sexual health, supporting the construct validity of these
fatigue cut-scores in breast cancer survivors. On the whole, Model A for the PFS-12 where
mild fatigue was conceptualized as 1–3, moderate fatigue as 4–6, and severe fatigue as 7–10
demonstrated better discrimination than Model D for HRQOL decrements among breast
cancer survivors. Moving forward, we recommend researchers and clinicians use Model A
cut-points and the PFS-12 measure. The fatigue severity thresholds for Model A are
preferred because they are clinically derived and consistent with conventions historically
used for the PFS-R and other established fatigue and HRQOL measures that use an 11-point
metric [1, 4, 22, 39]. The PFS-12 is recommended over the 22-item PFS as it has lower
response burden but maintains reliable and valid measurement of fatigue [38].
Our results are consistent with prior research of predictors of sexual health such as comorbid
conditions and emotional well-being [32–35]. Additional predictors with breast cancer
survivors have been identified as vaginal dryness, body image, quality of partner
relationship, and sexual problems with partner [30, 32–34]. Our study is distinctive in that
fatigue cut-score models explained approximately 30% of the variance in sexual
functioning, suggesting that fatigue should be explored as a predictor of sexual health and
potential mutable intervention target.
This study had limitations. First, with respect to selection bias, the HEAL sample included a
higher proportion with early stage and estrogen receptor-positive tumors than women
eligible in SEER [39]. No demographic differences between enrolled and eligible women
were found [39]. It may also be the case that the most fatigued women declined to enroll in
HEAL. Given the large proportion of early stage tumors in HEAL (62% Stages 0–1), only
about 30% received chemotherapy, which is a prime risk factor for fatigue in breast cancer
patients [57]. We attempted to more adequately represent the full range of fatigue severity,
disease stage, and treatment regimens by including women who experienced a recurrence or
new primary breast cancer. Future research should consider conducting prospective analyses
assessing fatigue by treatment group, disease stage, and hormone receptor status.
Given the sampling design across SEER sites, significant differences in demographic
characteristics existed between African-American and Caucasian survivor groups [1, 39].
Caucasian survivors were older and more likely to be married and have a college education
while African American survivors were more likely to be working. There were also more
deaths in the African-American group than Caucasian group before the HRQOL data was
collected at 3 years post-diagnosis. This may be, in part, a function of tumor types. Women
with triple negative disease (negative for hormone receptors and for HER2neu) tend to
relapse early and can have early deaths, but recurrence rates decrease over time after
diagnosis [58–60]. Women with hormone receptor-positive disease, which is most common
in Caucasian women, tend to have a low but constant risk of recurrence [60]. In the
MANCOVA and regression analyses, we controlled for race, age, education, stage,
treatment type, tamoxifen and antidepressant use, and comorbid conditions in an effort to
adjust for the influence of these factors.
Third, HEAL did not collect the PFS-R over time from diagnosis through survivorship and
used a modified recall of one month (instead of one week) [1]. This extended recall period
was intended to capture a general state of fatigue rather than acute episodes that may not be
representative of survivors’ overall fatigue experiences. Future research is needed to
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examine whether the cut-scores derived with a one-month recall period are also supported
for a one-week timeframe. Future studies would also benefit from the inclusion of
prospective fatigue measurement from women with all levels of fatigue, including very low
and high levels. Such a study might be facilitated by measures that reduce respondent
burden such as the PFS-12 [38].
A final limitation is that pre-diagnosis sexual health was assessed retrospectively. It may be
that breast cancer survivors were more positive in recalling their sexual functioning before
diagnosis than was actually the case. We controlled for pre-diagnosis sexual functioning in
analyses examining post-diagnosis sexual health as an outcome.
Additional research is also needed to examine the extent to which empirically-derived cut-
scores of fatigue severity can be useful in designating case definitions of cancer-related
fatigue (CRF) [13–16]. In addition to functional impairment, proposed criteria for case
definitions of CRF must necessarily take into account the presence of alternative proximal
causes for fatigue such as an endocrine disorder like hypothyroidism or a psychiatric
disorder like depression. This study did not assess emotional distress beyond the SF-36 and
antidepressant use. Psychometrically developed measures of emotional distress such as the
Depression, Anxiety, and Anger item banks developed by the Patient-Reported Outcomes
Measurement Information System® (PROMIS®) may be informative for these purposes
[61].
Two larger questions remain: 1.) Whether the cut-points identified for the PFS-R and
PFS-12 result in comparable groupings of individuals with equivalent levels of fatigue
severity when compared to other instruments; and 2.) Whether breast cancer survivors
identify the cut-scores as meaningful to them? These answers would be important to move
our field forward and enhance communication and reproducibility of results in cancer
fatigue research.
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Acronyms
BMI Body Mass Index
CIPS Cancer Inventory for Problem Situations
CRF Cancer-related fatigue
HEAL Health, Eating, Activity, and Lifestyle Study
HRQOL Health-Related Quality of Life
MANCOVA Multivariate Analysis of Covariance
MCS Mental Component Score for the SF-36
PCS Physical Component Score for the SF-36
PFS-R Piper Fatigue Scale- Revised
PFS-12 Piper Fatigue Scale-12
SEER Surveillance, Epidemiology, and End Results (cancer registries)
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SF-36 Medical Outcomes Study Short Form-36
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PFS-R and PFS-12 Models A and D Fatigue Severity Cut-Scores and Decrements in
Physical and Mental Health
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* Model A Fatigue Severity Cut-Scores: 0 (no fatigue), 1–3 (mild), 4–6 (moderate), 7–10
(severe fatigue)
** Model D Fatigue Severity Cut-Scores: 0 (no fatigue), 1–2 (mild), 3–5 (moderate), 6–10
(severe fatigue)
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PFS-R and PFS-12 Models A and D Fatigue Severity Cut-Scores and Decrements in
Physical and Mental Health
* Model A Fatigue Severity Cut-Scores: 0 (no fatigue), 1–3 (mild), 4–6 (moderate), 7–10
(severe fatigue)
* Model D Fatigue Severity Cut-Scores: 0 (no fatigue), 1–2 (mild), 3–5 (moderate), 6–10
(severe fatigue)
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PFS-R and PFS-12 Models A and D Fatigue Severity Cut-Scores and Decrements in Sexual
Health
* Model A Fatigue Severity Cut-Scores: 0 (no fatigue), 1–3 (mild), 4–6 (moderate), 7–10
(severe fatigue)
** Model D Fatigue Severity Cut-Scores: 0 (no fatigue), 1–2 (mild), 3–5 (moderate), 6–10
(severe fatigue)
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Table 1
Sample & Clinical Characteristics at Follow-Up Interview (N=857)
Demographics N (%) or
Mean ± SD
Clinical Characteristics N (%) or
Mean ± SD
Age at Diagnosis Stage of Breast Cancer
Mean age±SD 55.29±10.31 In situ-Stage 0 193 (22%)
Marital Status Localized-Stage I 342 (40%)
Married 473 (57%) Regional-Stage II a 160 (19%)
Widowed 105(13%) Stage II b 82 (10%)
Divorced/Separated 190 (22%) Stage III a 19 (2%)
Never Married 57 (7%) Unstaged 60 (7%)
Education Adjuvant Therapy
≤ High School Graduate 218 (25%) None 274 (32%)
Some College 311 (36%) Radiation Therapy 313 (37%)
College Graduate 166 (19%) Chemotherapy 82 (9%)
Graduate School 161 (19%) Radiation Therapy and Chemotherapy 188 (22%)
Employment Status Surgery
Working 474 (57%) No Surgical Procedure 14 (2%)
Not working – leave, retired, unemployed 319 (37%) Partial Mastectomy 552 (64%)
Not working - disabled 33 (4%) Total/modified Mastectomy 290 (34%)
Income Tamoxifen at follow-up
≤ 20,000 148 (18%) No 460 (56%)
20,001 – 50,000 284 (33%) Yes 368 (44%)
50,001 – 70,000 222 (27%)
≥70,000 118 (14%)
Race/Ethnicity Lymphedema
Non-Hispanic Caucasian 506 (67%) Never 681 (79%)
Non-Hispanic African American 224 (30%) Yes, not current 49 (6%)
Non-Hispanic Other 25 (3%) Yes, current 127 (15%)
Ethnicity: Hispanic 102 (12%)
Menopausal Status Bothered by Lymphedema in Past 3 Months
Post-menopausal 628 (76%) Not at all 49 (28%)
Pre-menopausal 151 (18%) A little/ A fair amount 108 (61%)
Unclassifiable 49 (6%) Much/Very much 19 (11%)
Smoking Status BMI
Not at all (or N/A) 729 (85%) < 25 377 (44%)
Every day 71 (9%) 25–29 239 (28%)
On some days 28 (3%) ≥ 30 241 (28%)
Comorbidities SEER Site
0 215 (26%) New Mexico 457 (53%)













Stover et al. Page 23
Demographics N (%) or
Mean ± SD
Clinical Characteristics N (%) or
Mean ± SD
1–2 400 (47%) Western Washington State 177 (21%)
≥3 213 (25%) Los Angeles County 223 (26%)
# Comorbid Conditions that Limit Activities Hormone Receptors
0 618 (75%) Estrogen receptor positive (ER+) 480 (56%)
1 145 (18%) Progesterone receptor positive (PR+) 386 (45%)
2 38 (5%) Antidepressants at Follow-Up
3–4 27 (2%) Yes 128 (15%)
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